Mondelez (MDLZ, $66.42) missed Q4 earnings expectations, but beat revenue estimates

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MDLZ just turned positive on October 30, 2026. Looking at past instances where MDLZ's MACD turned positive, the stock continued to rise in 24 of 44 cases over the following month. The odds of a continued upward trend are 55%.

MDLZ moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MDLZ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.

Following a +0.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLZ advanced for three days, in 168 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.

The Aroon Indicator entered an Uptrend today. In 103 of 220 cases where MDLZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.

Bearish Trend Analysis

The 10-day RSI Indicator for MDLZ moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 29 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 55 cases where MDLZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDLZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

MDLZ broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. MDLZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.163) is normal, around the industry mean (1.490). P/E Ratio (24.182) is within average values for comparable stocks, (15.433). Projected Growth (PEG Ratio) (0.891) is also within normal values, averaging (1.364). Dividend Yield (0.032) settles around the average of (0.163) among similar stocks. P/S Ratio (2.028) is also within normal values, averaging (1.937).